Jobs / United States / Abbvie US LLC
Senior Director Process Engineering Peptides API (Hybrid, IL)
Abbvie US LLC · 🇺🇸 North Chicago, IL, US
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 177 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 26 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Abbvie US LLC paid sponsored hires in similar roles10 certified filings for “ASSOCIATE DIRECTOR, STATISTICS” (Data Scientists) in IL: $117k–$165k, median $151k. Most were filed at wage level IV (50%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Abbvie US LLC
The US Department of Labor certified 177 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 26 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Abbvie US LLC →
About the role
Position Summary: The Sr Director Process Engineering Peptides API sets enterprise direction and senior technical governance for process engineering strategy, process platform deployment, process package design, technical assurance, manufacturing technology interfaces and project delivery for biologics drug substance and cell and gene therapy manufacturing within AbbVie Strategic Investment. The role supports Strategic Investments through engineering leadership, technical expertise, standards development, technical governance and project execution support across multiple manufacturing sites, strategic investments and technology platforms. The role supports engineering activities associated with peptides manufacturing facility investments, new production capabilities, strategic capacity creation, advanced manufacturing platforms and new technology deployments across the Strategic Investment portfolio. The role partners with Strategic Investments, manufacturing sites, operations, quality, EHS, validation / CQV and external engineering partners to deliver technically robust and business-aligned engineering solutions. Strategic Investment Context • Strategic Investment provides engineering leadership, technical governance, standards development and project execution support across AbbVie’s Strategic Investments and strategic capital portfolio. • The organization supports new biologics drug substance and cell and gene therapy manufacturing facilities, new platform deployments, strategic capacity creation, advanced biologics and CGT manufacturing capabilities and standards development for emerging technologies across Strategic Investments. • Strategic Investment roles are expected to promote common standards, transfer lessons learned across regions and sites, and enable consistent engineering delivery across strategic capital investments. Key Responsibilities: Strategic Investment Governance and Standards: • Establish, maintain and deploy global engineering standards, technical practices and governance expectations for biologics drug substance and cell and gene therapy process engineering strategy, process platform deployment, process package design, technical assurance, manufacturing technology interfaces and project delivery. • Drive consistent application of technical standards, design principles, lessons learned and engineering playbooks across regions, sites and capital projects. • Define enterprise standards, engineering requirements and technical guardrails for new biologics drug substance and cell and gene therapy technologies, including requirements for consistent design, deployment, qualification, operation and scale-up across Strategic Investments. • Ensure discipline strategies support AbbVie’s long-range Strategic Investment objectives, strategic investment programs and adoption of new technologies across future manufacturing platforms. • Provide governance and escalation for technical decisions with material safety, quality, compliance, cost, schedule, operability or lifecycle impact. Strategic New Technology and Capital Investment Support: • Provide engineering leadership for strategic capital investments, including new biologics drug substance and cell and gene therapy facility builds, technology platform deployments, new production capabilities, strategic capacity projects and lifecycle technology upgrades. • Support front-end engineering, facility concept development, investment option evaluation, manufacturing capability assessments and site / platform planning activities for biologics drug substance and cell and gene therapy assets. • Partner with Strategic Investments and project leadership to ensure technical assumptions, deliverables, risks and resource needs are integrated into capital